Evidence mapPaperPMID 40026705Full record

ArticleChemistry of materials : a publication of the American Chemical Society2025

Multifunctional Polypeptide-Based Nanoconjugates for Targeted Mitochondrial Delivery and Nonviral Gene Therapy.

Camilla Pegoraro, Esther Masiá Sanchis, Snežana Đorđević, Irene Dolz-Pérez, Cristián Huck-Iriart, Lidia Herrera, Sergio Esteban-Pérez, Inmaculada Conejos-Sanchez, María J Vicent

Abstract read
In one paragraph

Article in Chemistry of materials : a publication of the American Chemical Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Self-Assembling Short Peptide Carriers for Gene Delivery.International journal of molecular sciences · 2026
    Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Camilla PegoraroPríncipe Felipe Research Center, Polymer Therapeutics Lab., Valencia 46012, Spain.
Esther Masiá SanchisPríncipe Felipe Research Center, Polymer Therapeutics Lab., Valencia 46012, Spain.
Snežana ĐorđevićPríncipe Felipe Research Center, Polymer Therapeutics Lab., Valencia 46012, Spain.ORCID https://orcid.org/0000-0001-8429-7486
Irene Dolz-PérezCurapath, Av. Benjamin Franklin 19, Paterna, Valencia 46980, Spain.ORCID https://orcid.org/0000-0002-0447-0718
Cristián Huck-IriartExperiments Division, ALBA Synchrotron Light Source, Cerdanyola del Vallès 08209, Spain.ORCID https://orcid.org/0000-0001-5734-2499
Lidia HerreraCurapath, Av. Benjamin Franklin 19, Paterna, Valencia 46980, Spain.
Sergio Esteban-PérezCurapath, Av. Benjamin Franklin 19, Paterna, Valencia 46980, Spain.
Inmaculada Conejos-SanchezPríncipe Felipe Research Center, Polymer Therapeutics Lab., Valencia 46012, Spain.ORCID https://orcid.org/0000-0002-4196-0855
María J VicentPríncipe Felipe Research Center, Screening Platform., Valencia 46012, Spain.ORCID https://orcid.org/0000-0001-7771-3373

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite recent advances in nanomedicine, developing multifunctional nanocarriers capable of targeted subcellular delivery and efficient gene therapy remains a significant challenge. This study reports the design, synthesis, and evaluation of a novel multifunctional polypeptide-based nanoconjugate that addresses this gap using sequential delivery, combining mitochondrial targeting and nonviral gene therapy. We engineered a poly-l-ornithine-based, polyethylene glycol-modified carrier and introduced a novel custom-designed trivalent compound (TRV3) into the structure. TRV3, conjugated to the polypeptide carrier via a redox-sensitive disulfide linker, incorporates the well-described triphenylphosphonium moiety (TPP) for mitochondrial targeting and a Cy5 fluorophore as a model drug. The resulting nanoconjugate (C-TRV3-A) demonstrated efficient endosomal escape and mitochondrial localization. Leveraging the endosomolytic properties of C-TRV3-A, we explored its potential as a nonviral vector for gene therapy. After optimizing formulation stability using a VLC-3 anionic polypeptide coating, we developed plasmid DNA polyplexes that exhibited enhanced stability and transfection efficiency in basic and advanced triple-negative breast cancer cell culture models. This multifunctional polypeptide-based nanoconjugate represents a significant advance in the field, offering a chemically versatile platform for simultaneous subcellular targeting and gene delivery that may be used in targeted cancer treatments, among other pathologies.

Identifiers

PMID40026705
PMCPMC11866743

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.